THAL for THAL?

Blood

Volumn 110, Issue 8, 2007, Pages 2788-2789

  Chui, David H K ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE BUTYRATE; ARGININE DERIVATIVE; AZACITIDINE; CYTOKINE; ERYTHROPOIETIN; FETAL GAMMA GLOBIN; GENE PRODUCT; HEMOGLOBIN; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; THALIDOMIDE; UNCLASSIFIED DRUG;

BLOOD TRANSFUSION; DRUG MECHANISM; ERYTHROID CELL; EX VIVO STUDY; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; MALARIA; NOTE; PATIENT CARE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PUBLIC HEALTH; RISK FACTOR; SICKLE CELL ANEMIA; SURVIVAL; THALASSEMIA;

EID: 35548950993     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-08-102913     Document Type: Note

References (7)

1. Weatherall DJ. The challenge of thalassemia for the developing countries. Ann NY Acad Sci. 2005;1054:11-17.
2. Pauling L, Itano HA, Singer SJ, Wells IC. Sickle cell anemia, a molecular disease. Science. 1949;110:543-548.
3. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289:1645-1651.
4. +- thalassemia. N Engl J Med. 1982;307:1469-1475.
5. Ley TJ, DeSimone J, Noguchi CT, et al. 5′-Azacytidine increases γ-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. Blood. 1983;62:370-380.
6. Perrine SP, Ginder GD, Faller DV, et al. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the β-globin disorders. N Engl J Med. 1993;328:81-86.
7. Musto P, Falcone A, Sanpaolo G, Bisceglia M, Matera R, Carella AM. Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes. Haematologica. 2002;87:884-885.